title: Heart rate variability in myocardial infarction and heart failure.
abstract: The need to refine the identification of patients who might benefit from implantation of an implantable cardioverter defibrillator has been risen by the results of many clinical trials on ICD therapy. Traditional parameters such as left ventricular ejection fraction and the presence of non-sustained ventricular tachycardia were not strong enough to achieve this goal with reasonable cost-effectiveness. Heart rate variability (HRV) is one of the most popular parameters used to assess the autonomic tone. HRV has been reported as a strong predictor of cardiovascular mortality. Currently, three different categories of methods in HRV analysis are being used; the time domain, frequency domain, and non-linear dynamic analysis. Both time domain and frequency domain analyses of HRV have been investigated extensively regarding their use as a prognostic marker for cardiovascular mortality. The non-linear dynamic analysis is the latest tool that has shown to have an even higher predictive value than any of the traditional parameters. However, standardized and supporting evidence on this new technique is still lacking. In this article, the current role of HRV in the prediction of cardiovascular mortality in myocardial infarction and heart failure patients has been reviewed.
authors.affiliation: Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. nchattip@mail.med.cmu.ac.th
authors.forename: Nipon
authors.initials: N
authors.lastname: Chattipakorn
authors.forename: Tanat
authors.initials: T
authors.lastname: Incharoen
authors.forename: Natnicha
authors.initials: N
authors.lastname: Kanlop
authors.forename: Siriporn
authors.initials: S
authors.lastname: Chattipakorn
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D015415:Biomarkers; D001026:Coronary Artery Bypass; D006333:Heart Failure / Q000503:physiopathology* / Q000628:therapy; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology* / Q000628:therapy; D015425:Myocardial Reperfusion
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D015415:Biomarkers